- The Phase 2 RedirecTT-1 study shows a 78.9% overall response rate with TALVEY and TECVAYLI in multiple myeloma patients.
- 83.3% of patients previously treated with BCMA CAR-T therapy responded to this combination therapy.
- 61% progression-free survival and 74.5% overall survival rate at one year were observed in study participants.
In a significant advancement for multiple myeloma treatment, Johnson & Johnson (JNJ, Financial) announced promising results from the Phase 2 RedirecTT-1 study. The study evaluated the efficacy of combining TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) in patients with relapsed/refractory multiple myeloma and true extramedullary disease (EMD). An impressive 78.9% of participants achieved an overall response, with over half attaining complete responses or better.
The trial enrolled 90 heavily pretreated patients, including those previously exposed to BCMA CAR-T therapy and anti-FcRH5 bispecific antibodies. Among these, response rates were notably high: 83.3% for BCMA CAR-T-exposed patients and 75% for those previously treated with bispecific antibodies against FcRH5.
The durability of the responses was highlighted by a median follow-up of 13.4 months, with 66.2% of responders maintaining their response at the data cutoff. Furthermore, 61% of the patients remained progression-free at one year, and the survival rate at that milestone was 74.5%.
Safety profiles for the combination were consistent with previous treatments, with the most common side effects being cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), largely at low grades. The treatment regimen allows for once-monthly dosing, which could enhance patient adherence and quality of life.
These results, presented at the 2025 European Hematology Association Congress, underscore the potential for TALVEY and TECVAYLI to redefine treatment strategies for patients with extramedullary multiple myeloma, offering hope to those who have exhausted conventional therapies.
